March 14, 2026. 5 articles reviewed below the CED clinical relevance threshold of 35. Listed in descending order of score.
He got Connecticut’s first cannabis license. Now he’s betting on medical marijuana again
This article covers a Connecticut cannabis licensee’s business expansion into new product lines and laboratory capabilities, which may interest clinicians tracking commercial medical cannabis product development and market trends.
Read more →Trulieve to Open Medical Cannabis Dispensary in DeLand, Florida – Stock Titan
Summary This article announces Trulieve’s opening of medical cannabis dispensaries in Florida locations, which may interest clinicians monitoring retail cannabis access expansion and market developments in regulated medical cannabis states.
Read more →Bipartisan Senate Bill Would Create Psychedelic-Focused VA Research Centers To Explore …
Summary Senate bill proposes VA research centers for psychedelics; relevant to cannabis clinicians as both substances are emerging therapeutic areas with similar regulatory and clinical research trajectories.
Read more →Snoop Dogg Refused Federal Trademark on ‘Smoke Weed Everyday’ for Marijuana Brand
Summary Federal trademark denial for cannabis brand naming illustrates regulatory barriers affecting commercial cannabis operations and intellectual property considerations in the industry.
Read more →Kansas City Mavericks at Tahoe Knight Monsters – Mountain Democrat Events
This article announces a minor league hockey game between Kansas City and Tahoe teams; it has no cannabis-related content or clinical relevance.
Read more →Digest-Level Clinical Commentary
The expansion of medical cannabis retail infrastructure, particularly through established operators like Trulieve opening multiple locations, suggests growing normalization and accessibility that will likely increase patient inquiries in primary care settings, requiring us as physicians to develop more robust clinical frameworks for patient selection and monitoring. The parallel movement toward psychedelic research centers signals a broader institutional shift in how federal and state entities view plant-based therapeutics, which could create opportunities for more rigorous clinical evidence generation around cannabis but also risks positioning cannabinoid medicine within a “alternative” rather than mainstream pharmacological paradigm. These developments underscore the urgency for family physicians to engage with cannabis medicine through evidence-based education rather than ceding this clinical space to dispensary staff or unregulated practitioners.
These items reflect several concurrent developments in cannabis and psychedelic policy and commerce. The expansion of medical cannabis dispensaries and product innovation suggests an increasingly normalized regulatory environment for cannabis in certain states, while emerging federal interest in psychedelic research through the VA indicates potential clinical pathways for novel therapeutics. Trademark and branding challenges highlight the ongoing tension between state-level cannabis legalization and federal scheduling restrictions that continue to limit business operations in this space.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: